Endo International plc

From Wikipedia, the free encyclopedia
  (Redirected from Endo Pharmaceuticals)
Jump to: navigation, search
Endo International plc
S&P 500 Component
Industry Pharmaceutical
Headquarters Dublin, Ireland and Malvern, Pennsylvania, U.S.
Website www.endo.com

Endo International plc is global specialty healthcare company. It was created as a result of a management buyout from DuPont Merck in 1997. Three DuPont Merck executives (Carol A. Ammon, Chairman, President & CEO, and Mariann T. MacDonald, Executive Vice President, Operations, along with another colleague) purchased all of Endo Laboratories L.L.C.'s generic products along with 12 important brand products, including Percocet, Percodan, and Opana. The new company was called "Endo Pharmaceuticals Inc."

Endo acquired Algos Pharmaceutical Corporation through a merger in July 2000 and began to trade publicly (NASDAQENDP). Endo successfully completed a secondary offering for a total of 12,925,000 shares of its common stock in Oct 2001. The net proceeds were used to pay existing bank debt.

On February 28, 2014, Endo completed its acquisition of Paladin Labs, a leading Canada-based specialty pharmaceutical company. Endo and Paladin Labs came together under Endo International plc and Endo established new global headquarters in Dublin, Ireland.

Endo develops, manufactures, markets and distributes quality branded pharmaceutical, generic and device products though its operating companies. The company has global headquarters in Dublin, Ireland and U.S. headquarters in Malvern, PA.

Corporate governance[edit]

As of March 2013,[1] Endo's chief executive officer (CEO) was Rajiv De Silva.[2]

As of September 2013, Endo's chief financial officer (CFO) was Suketu Upadhyay.[citation needed] A prior CFO, Charles A. Rowland Jr., had been appointed in December 2006.[2]



Endo Pharmaceuticals once had the United States marketing rights for the FDA-approved Synera anesthetic patch for needle procedures. The agreement of 6 January 2006 for Endo Pharmaceuticals to market Synera (lidocaine plus tetracaine patch) was terminated on 31 July 2008.  Endo is no longer involved with the Synera patch in the United States.  Zars Pharmaceuticals was the patent holder for Synera.[4] The rights to Synera passed to Nuvo Research of Canada in May 2011 upon the acquisition of ZARS Pharmaceuticals by Nuvo Research.[5] Upon its purchase of Paladin Labs of Montreal, Endo once again became involved with the Synera patch by acquiring the rights to market Synera in Canada upon the approval of the Synera patch by Health Canada.[6][7]


In 2009, Endo bought Indevus Pharmaceuticals to diversify into endocrinology and oncology.[8] The company entered the male hypogonadism market later in 2010 with Fortesta 2% gel.[8]

On November 4, 2010, Endo acquired Penwest Pharmaceuticals.

On December 1, 2010, Endo acquired generics company, Qualitest Pharmaceuticals.

On June 20, 2011, Endo acquired medical device company, American Medical Systems Inc (AMS).

In November 2013, Endo agreed to purchase Paladin Labs Inc for about $1.6 billion to gain access to the Canadian market as well as expand into emerging markets.[7] The acquisition was finalized February, 2014.

On February 3, 2014, Endo successfully completed its acquisition of specialty generics company Boca Pharmacal. On July 24, 2014, Endo completed its purchase of Somar, a privately-owned specialty pharmaceuticals company based in Mexico City. In August 2014, Endo completed its purchase of Dava Pharmaceuticals, Inc., a privately-held generic pharmaceuticals manufacturer. In October 2014, Endo International said it would buy Auxilium Pharmaceuticals for $2.6 billion.[9] That transaction was completed by January 2015 the company said in Dublin[10] after receiving all the regulatory approvals the deal needed.

Acquisition attempts[edit]

In early 2014, Endo sought to acquire NuPathe, a speciality pharmaceutical developer, for US$105,000,000.[11] However, Teva prevailed in this acquisition with a substantially higher bid.[12]

Mesh litigation and liabilities[edit]

With the acquisition of American Medical Systems Inc (AMS), Endo accepted to settle mesh claims. The mesh liabilities have ballooned to billions since even after settling thousands of claims.


  1. ^ "Management Team". About Us. Endo Pharmaceuticals. Rajiv De Silva. Retrieved 2015-08-05. [self-published source]
  2. ^ a b Staff (6 December 2006). "Endo Pharmaceuticals names new CFO". The News Journal (Delaware). Retrieved 2015-08-05. (subscription required)
  3. ^ "Product Listing". Endo Pharmaceuticals. 2006. Retrieved 2006-12-06. 
  4. ^ http://www.wikinvest.com/stock/Endo_Pharmaceuticals_Holdings_%28ENDP%29/Zars%20Pharma
  5. ^ http://www.prnewswire.com/news-releases/nuvo-research-completes-its-acquisition-of-zars-pharma-121767618.html
  6. ^ http://www.marketwired.com/press-release/paladin-labs-nuvo-research-sign-canadian-license-agreement-synera-loan-agreement-tsx-plb-1662022.htm
  7. ^ a b Bloomberg (2013-11-04). "Endo to buy Paladin labs". Bloomberg. Retrieved 2013-11-04. 
  8. ^ a b Associated Press (2009-01-06). "Endo to buy Indevus". The Boston Globe. Retrieved 2009-06-28. 
  9. ^ http://www.genengnews.com/gen-news-highlights/endo-scores-with-2-6b-offer-for-auxilium-which-ends-qlt-deal/81250454/
  10. ^ Endo Completes Acquisition Of Auxilium Pharmaceuticals, Endo corporate website, 29 January 2015.Retrieved: 9 May 2016.
  11. ^ "Endo to Purchase NuPahte for $150M+". News: Industry Watch. Gen. Eng. Biotechnol. News (paper) 34 (2). January 15, 2014. p. 10. 
  12. ^ "Teva Outbids Endo, Acquires NuPathe for $144M+". News: Industry Watch. Gen. Eng. Biotechnol. News (paper) 34 (4). February 15, 2014. p. 10. 

External links[edit]